Source trace. Via News points to the documents behind its reporting and shows what we drew from each, so you can check any claim. How we source
Source document· November 24, 2025
Lilly to highlight progress across key programs in early and advanced hormone receptor-positive breast cancer at the 2025 San Antonio Breast Cancer Symposium
View original at finance.yahoo.comLilly to highlight progress across key programs in early and advanced hormone receptor-positive breast cancer at the 2025 San Antonio Breast Cancer Symposium Updated results from the Phase 3 EMBER-3 trial for Inluriyo™ (imlunestrant) alone and in combination with Verzenio® (abemaciclib) in ER+, HER2– metastatic breast…
Ce que nous avons tiré de cette source
The claims Via News extracted from this document. We point to the source; we don't replace it.
PIK3CA mutations are present in approximately 40% of HR+/HER2- breast cancers
80% confidenceESR1 mutations are a key driver in ER+ breast cancer resistance
80% confidenceHR+, HER2- breast cancer is the most common form of breast cancer
80% confidenceEli Lilly has nearly 150 years of history pioneering discoveries
80% confidenceVerzenio has been authorized in more than 90 countries
80% confidenceAt SABCS 2025, Eli Lilly is showcasing new data across their portfolio addressing the three most important biologic targets in HR+ breast cancer: CDK4/6, the estrogen receptor, and PI3K, reflecting continued momentum and commitment to translating biologic conviction into meaningful progress
80% confidence
